FFA
LGND icon

Farther Finance Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Farther Finance Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$54K Sell
173
-46
-21% -$13.6K ﹤0.01% 3347
2026
Q2 		$69.1K Sell
219
-499
-69% -$118K ﹤0.01% 2989
2026
Q1 		$143K Buy
718
+73
+11% +$14.4K ﹤0.01% 2256
2025
Q4 		$122K Sell
645
-34
-5% -$6.53K ﹤0.01% 2218
2025
Q3 		$120K Buy
679
+41
+6% +$6.09K ﹤0.01% 1922
2025
Q2 		$72.5K Buy
638
+5
+0.8% +$534 ﹤0.01% 1933
2025
Q1 		$66.4K Sell
633
-133
-17% -$15K ﹤0.01% 1753
2024
Q4 		$82.1K Sell
766
-10
-1% -$1.13K ﹤0.01% 1401
2024
Q3 		$77.7K Buy
776
+74
+11% +$7.45K ﹤0.01% 1427
2024
Q2 		$59.6K Buy
702
+625
+812% +$49.7K ﹤0.01% 1348
2024
Q1 		$5.67K Sell
77
-5
-6% -$369 ﹤0.01% 2009
2023
Q4 		$5.86K Buy
+82
New +$4.84K ﹤0.01% 1885

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $636M AUM 21.4% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return

Farther Finance Advisors's LGND Position: Q3 2026 in Review

Farther Finance Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 21% in Q3 2026, selling an estimated $13.6K and leaving 173 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #3347.

Farther Finance Advisors first reported a position in LGND in Q4 2023 and has held it in 12 quarters since. The position peaked at $143K in Q1 2026. 14 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Farther Finance Advisors held 173 shares of Ligand Pharmaceuticals worth $54K as of Q3 2026.
  • Farther Finance Advisors sold 46 Ligand Pharmaceuticals shares in Q3 2026, an estimated $13.6K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3347 holding.
  • Farther Finance Advisors first reported a position in Ligand Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Ligand Pharmaceuticals position peaked at $143K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.